What is the mechanism of action of CJC-1295 + Ipamorelin Blend?

CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What route should I use for CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What should I look for in CJC-1295 + Ipamorelin Blend sourcing and quality?

Acceptable CJC-1295 + Ipamorelin Blend certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching Variable, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What class of compound is CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend is classified as a GHRH + GHRP combination. Within this class, alternative names and analogues include CJC/Ipa, GH-Releasing Stack. The class-level pharmacology shapes both the clinical applications and the safety profile; the female physiology literature treats CJC-1295 + Ipamorelin Blend alongside its class peers when evaluating relative merits.

How does CJC-1295 + Ipamorelin Blend interact with female hormonal cycling?

Cyclical hormone background influences how CJC-1295 + Ipamorelin Blend is distributed, metabolised, and felt. Even where the compound's pharmacology is not directly hormonal, response often varies across follicular and luteal phases. Premenopausal users should track by cycle phase for 1–2 cycles before settling on a fixed schedule; perimenopausal users benefit from integration with HRT where indicated.

Should I cycle CJC-1295 + Ipamorelin Blend?

Standard cycle for CJC-1295 + Ipamorelin Blend is 8–12 weeks of 1-3x daily subq 100 mcg CJC + 200 mcg ipamorelin dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to CJC-1295 + Ipamorelin Blend's Mixed half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Home/ Compounds/ CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend

Women's Health

For women considering CJC-1295 + Ipamorelin Blend, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. The canonical GHRH + GHRP stack — synergistic GH release with minimal off-target effects on cortisol or prolactin. The Mixed pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.

Female Physiology Applications

PCOS SupportEndometriosis SupportBone DensityHair HealthSkin Health

Key Takeaways

Female-physiology lens: CJC-1295 + Ipamorelin Blend response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Cyclical hormone background shapes how women experience CJC-1295 + Ipamorelin Blend. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.

Fertility and reproductive considerations

CJC-1295 + Ipamorelin Blend's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, CJC-1295 + Ipamorelin Blend is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and CJC-1295 + Ipamorelin Blend's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Female Physiology Applications

Endometriosis Support

Endometriosis Support is one of the dimensions on which women track CJC-1295 + Ipamorelin Blend response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Fertility

For fertility in female users, CJC-1295 + Ipamorelin Blend is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Cycle Support

In the perimenopausal window, CJC-1295 + Ipamorelin Blend for cycle support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Hair Health

Hair Health is one of the dimensions on which women track CJC-1295 + Ipamorelin Blend response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg CJC + 200 mcg ipamorelin	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg CJC + 200 mcg ipamorelin	4–6 weeks initial cycle
Women's Health focus	SubQ	100 mcg CJC + 200 mcg ipamorelin	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg CJC + 200 mcg ipamorelin	Ongoing with periodic pauses

Dose timing for CJC-1295 + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

CJC-1295 + Ipamorelin Blend + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in female physiology protocols.
CJC-1295 + Ipamorelin Blend + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in female physiology protocols.
CJC-1295 + Ipamorelin Blend + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in female physiology protocols.
CJC-1295 + Ipamorelin Blend + Epithalon: Identified by Khavinson in St. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Both components banned (S2) FDA: Unapproved Research: Off-label clinical use; mechanistic studies

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible.

Lens-specific safety considerations for female physiology use of CJC-1295 + Ipamorelin Blend: Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Ipamorelin selective GH secretagogue

PMID 9849822

CJC-1295 + Ipamorelin Blend vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 + Ipamorelin Blend	GHRH + GHRP combination	Mixed	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Is CJC-1295 + Ipamorelin Blend appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Does CJC-1295 + Ipamorelin Blend affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where CJC-1295 + Ipamorelin Blend specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

Can I use CJC-1295 + Ipamorelin Blend alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

How long until I see results from CJC-1295 + Ipamorelin Blend?

Acute effects from CJC-1295 + Ipamorelin Blend appear within the first week for downstream physiological adaptation. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend (also known as CJC/Ipa / GH-Releasing Stack) is a small ghrh + ghrp combination with a molecular weight of Variable and a plasma half-life of Mixed. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The compound is studied primarily in the female physiology domain for the applications outlined above.

Clinical Protocol

Start a CJC-1295 + Ipamorelin Blend Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified CJC-1295 + Ipamorelin Blend and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Both components banned (S2)
FDA: Unapproved
Research: Off-label clinical use; mechanistic studies

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for CJC-1295 + Ipamorelin Blend

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised